Effect of Bacteriophages and Gentamycine on Morphology and Vesicle Formation of Bacteria Yersinia pestis EV

Objective was to assess the effect of specific bacteriophages and gentamycine on the morphological-functional properties of bacteria in the vaccine strain Yersinia pestis EV.Materials and methods. The vaccine strain Y. pestis EV, Pokrovskaya bacteriophage and the pseudotuberculous diagnostic bacteriophage were used for the study. The microbial culture was grown on solid and in liquid growth media at 27 °C for 20–24 h. The co-incubation of bacteria and bacteriophage or gentamycine was carried out at 27 °C for 20 minutes or at 37 °C for 2 hours, respectively. Culture preparations were examined by transmission electron microscopy.Results and discussion. The influence of cultivation conditions and various stress factors on the vesicle production by the vaccine strain Y. pestis EV cells was evaluated. The nature and intensity of morphological-functional changes in Y. pestis EV cells in response to the effect of bacteriophages (plague Pokrovskaya and pseudotuberculous bacteriophages) or an antibiotic (gentamycine) were determined. It was established that co-incubation of Y. pestis EV with Pokrovskaya bacteriophage or gentamycine for 20 min leads to the increase in the production of extracellular vesicles and is accompanied by the development of degenerative changes in bacterial cells

Electron-Microscopic Investigation of Interactions between <I>Yersinia pseudotuberculosis</I>, <I>Yersinia pestis</I> Cells and Specific Bacteriophages

Carried out has been electron-microscopic investigation of dynamics of interactions between Yersinia pseudotuberculosis, Yersinia pestis cells and specific bacteriophages in vitro. Identified have been peculiarities in morphological manifestation of the interactions. Determined are morphometric characteristics of the bacteriophages utilized in the experiment. It is demonstrated that after 40 minutes of co-incubation of Y. pseudotuberculosis with specific bacteriophage emergence of persisting forms of microbial cells is observed, while in case of EV strain infecting with Pokrovskaya bacteriophage, this phenomenon is not detected

IMMUNOCHEMICAL STUDY OF RECEPTION OF PLAGUE BACTERIOPHAGE POKROVSKY

Aim. Study of mechanism of reception of plague bacteriophage Pokrovsky to cells of Yersinia pestis using a panel of monoclonal antibodies. Materials and methods. Using a method of competitive inhibition, the ability of monoclonal antibodies against antigenic epitopes of outer membrane of Yersinia genus bacteria to inhibit adhesion of the studied bacteriophage to cells of Y. pestis EV strain, was evaluated. Results. A key role of structure of carbohydrate nature in reception of Pokrovsky bacteriophage was confirmed. Among 5 lines of monoclonal antibodies against protein epitopes 2 were established to cause significant inactivation of bacteriophage adhesion to bacterial cells. Conclusion. An assumption is proposed regarding participation of a structure of polypeptide nature in reception of Pokrovsky bacteriophage by cells of plague microbe

The efficacy of therapy with rituximab (R-CHOP) in patients with diffuse large cells lymphoma

<p>This study aimed to evaluate treatment results in patients with diffuse large cell lymphoma (DBL CL) received R-CHOP program (as 1 st and<br />2 nd line therapy), including cases with complications. We observed 77 DBLCL patients (50 primary and 27 received other chemotherapy programs, in relapse, progression or treatment resistance phase). The median age is 54.1 years (21–79 years). 33 patients (43 %) had a high risk for unfavorable disease course according to IPI. Complications associated with development of severe compression syndromes, which required the appropriate surgical intervention, w as diagnosed in 45 (58.4 %) patients. From 50 primary patients received R-C HOP as the f irst line therapy objective treatment response was registered in 47 (94.0 %). Complete response was registered in 43 (86.0 %). The proportion of patients in whom response was maintained for 6 months w as 72.0 % in group with maintenance therapy and 28.0 % in group without it. These results were achieved when induction period density was 0.9. The last parameter is the ratio of the courses number to their time in mon ths. The density of standard induction R-C HOP-21 is 1.4. From 27 relapse or refractory patients received R-C HOP as the second line therapy objective<br />treatment response was registered in 85.1 % of patients. Induction period density w as 1.03. The proportion of patients in whom response was maintained for 6 months was 74.0 %. Three classes serum Ig concentrations analysis before and after induction period in 16 pati ents showed normal values. With the median (Me) follow-up time in all patients over 24 months 3-years survival w as 93 % and Me w as not achieved. 3-years survival was 100 % in primary patients and 80 % in patients with previously treatment, and Me is also not achieved.</p

Treatment efficacy of chronic myeloid leukemia with imatinib in clinical practice

Imatinib (IM) treatment efficacy in 116 chronic myeloid leukemia (CML) patients in different studies was analyzed. Patient group was non‑selective with prospective enrollment. The study was based on real‑time patient’s register allows to treatment quality control due to clinical results. Cytogenetic response (CO), hematological data, and overall survival (OS) were used as criteria for the therapy efficacy. After 12 month of treatment in 46.4 % of CML patients in early chronic phase complete CO (CCO) was obtained, in 33.3 % — in the late chronic phase, and in 13.3 % — in accelerated phase. Deficit of daily imatinib dose and intervals in treatment schedule were made a negative influence on CO quality. The median of OS was 120 months.</p

Treatment of patients with refractory chronic lymphocytic leukemia with alemtuzumab, alone or in combination with fludarabine

In present study the immediate and long-term therapy results of 14 patients with refractory chronic lymphocytic leukemia (CLL) are analyzed. Treatment program included alemtuzumab alone or in combination with fludarabine.</p